These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7203915)

  • 21. The effect of fasting on gallbladder opacification during oral cholecystography: a controlled study in normal volunteers.
    Loeb PM; Berk RN; Janes JO; Perkin L; Moore J
    Radiology; 1978 Feb; 126(2):395-401. PubMed ID: 341220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Excretion and distribution of iophenoxic acid.
    Mudge GH; Strewler GJ; Desbiens N; Berndt WO; Wade DN
    J Pharmacol Exp Ther; 1971 Jul; 178(1):159-72. PubMed ID: 5087394
    [No Abstract]   [Full Text] [Related]  

  • 23. Fractionated dose cholecystography: a comparison between iopanoic acid and sodium ipodate.
    Reiner RG; Lawson MJ; Davies GT; Tucker WG; Mileski O; Read TR; Grant AK
    Clin Radiol; 1980 Nov; 31(6):667-9. PubMed ID: 7214807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiographic appearance of the nonabsorbed (unconjugated) and conjugated sodium tyropanoate (Bilopaque) in the bowel.
    Muhletaler CA; Gerlock AJ; Amberg JR; Avant GR
    Invest Radiol; 1982; 17(5):506-9. PubMed ID: 7141832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subjective vs. objective evaluation of gallbladder opacification during oral cholecystography in comparative clinical trials: implications for studies involving visual assessment.
    Fon GT; Hunter TB; Berk RN; Patton DD; Capp MP
    Radiology; 1982 Jul; 144(2):277-80. PubMed ID: 7089280
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastrointestinal absorption of iopanoic acid.
    Nelson JA; Moss AA; Goldberg HI; Benet LZ; Amberg J
    Invest Radiol; 1973; 8(1):1-8. PubMed ID: 4685376
    [No Abstract]   [Full Text] [Related]  

  • 27. The role of cholecystokinin in radiographic opacification of the gallbladder.
    Herzog RJ; Nelson JA
    Invest Radiol; 1976 SEP-OCT; 11(5):440-7. PubMed ID: 977262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral cholecystography in the early phase of acute alcoholic pancreatitis. A prospective, randomized comparison of Telepaque and Bilopaque.
    Smith HJ; Corbett DB; Loeb PM; Peterson WL
    Invest Radiol; 1982; 17(6):629-33. PubMed ID: 6759457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined cholangiography and cholecystography using sodium iopanoate.
    Koehler RE; Goldberg HI
    Invest Radiol; 1977; 12(3):267-72. PubMed ID: 863631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and preliminary pharmacologic evaluation of a zwitterionic oral cholecystographic agent.
    Sovak M; Barnhart JL; Ranganathan R; Schulze PE; Siefert HM; Speck U
    Invest Radiol; 1981; 16(6):513-6. PubMed ID: 7319759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Residual contrast medium in the bowel in cholecystography with iopanoic acid and certain related substances.
    ANDREN L; THEANDER G
    Acta radiol; 1960 May; 53():371-6. PubMed ID: 13793563
    [No Abstract]   [Full Text] [Related]  

  • 32. Cholangiographic excretion studies. Solu-Biloptin and Biligrafin comparison.
    Benness GT; Evill CA; Soschko M
    Invest Radiol; 1975; 10(5):526-31. PubMed ID: 1205712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Absorption of iopanoic acid and its sodium salt.
    HOLMDAHL KH SON ; LODIN H
    Acta radiol; 1959 Apr; 51(4):247-50. PubMed ID: 13649372
    [No Abstract]   [Full Text] [Related]  

  • 34. The choleretic action of sodium tyropanoate (bilopaque sodium) in the dog: preliminary observation.
    Nelson JA; Straubus AE; Amberg JR
    Invest Radiol; 1974; 9(6):438-43. PubMed ID: 4430583
    [No Abstract]   [Full Text] [Related]  

  • 35. Toxicologic and pharmacologic properties of iocetamic acid, a new oral cholecystographic agent.
    Janbroers JM; Sanders JC; Til HP; Feron VJ; De Groot AP
    Toxicol Appl Pharmacol; 1969 Mar; 14(2):232-41. PubMed ID: 5772846
    [No Abstract]   [Full Text] [Related]  

  • 36. The consecutive dose phenomenon in oral cholecystography.
    Berk RN
    Am J Roentgenol Radium Ther Nucl Med; 1970 Oct; 110(2):230-4. PubMed ID: 5472655
    [No Abstract]   [Full Text] [Related]  

  • 37. The pharmaco-kinetics of telepaque metabolism: the relation of blood concentration and bile flow to the rate of hepatic excretion.
    Dunn CR; Berk RN
    Am J Roentgenol Radium Ther Nucl Med; 1972 Apr; 114(4):758-66. PubMed ID: 5026241
    [No Abstract]   [Full Text] [Related]  

  • 38. Biopharmaceutical factors influencing the intestinal absorption of iopanoic acid.
    Goldberger LE; Berk RN; Lang JH; Loeb PM
    Invest Radiol; 1974; 9(1):16-23. PubMed ID: 4813207
    [No Abstract]   [Full Text] [Related]  

  • 39. ORAGRAFIN AS A SUPPLEMENTAL CONTRAST AGENT IN ORAL CHOLECYSTOGRAPHY.
    RICHARDSON GA; SCHREIBER MH
    Tex State J Med; 1963 Aug; 59():788-9. PubMed ID: 14044597
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical comparison of tyropanoate sodium, ipodate sodium, and iopanoic acid.
    Russell JG; Frederick PR
    Radiology; 1974 Sep; 112(3):519-23. PubMed ID: 4843279
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.